Pre-approval access for efgartigimod in CIDP
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This program provides early access to an investigational medication called efgartigimod for adults with CIDP who haven't responded well to usual treatments. The drug aims to reduce the immune attack on nerves and may help manage symptoms when other options fail.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of CIDP.
- Your condition must still be active or getting worse, even after trying standard treatments like steroids or immunoglobulin therapy.
- You cannot be in another clinical trial, and standard approved treatments must not be working well for you.
- You cannot be pregnant, planning to become pregnant, or breastfeeding.
- You should not have other autoimmune diseases or conditions that could interfere with the study, and you cannot be taking certain biologic medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This study is for women who have taken efgartigimod (a medicine for certain autoimmune conditions) right before or during pregnancy, or while breastfeeding. Researchers will monitor moms, fetuses, and babies to check for side effects and ensure safety.
This study tests a new medicine called efgartigimod to see if it can help people with Sjogren's disease who have nerve damage (neuropathy). You may be able to join if your nerve symptoms started within the last 5 years and are getting worse.
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
Hear when a new CIDP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.